Traders Focused Stocks: Clovis Oncology, Inc. (CLVS), ConocoPhillips (COP)

Olive Hawkins
January 13, 2018

Copper Rock Capital Partners Llc sold 44,645 shares as the company's stock declined 15.57% while stock markets rallied.

Group One Trading Lp, which manages about $11.01 billion US Long portfolio, decreased its stake in Myriad Genetics Inc (Put) by 22,500 shares to 46,600 shares, valued at $1.69M in 2017Q3, according to the filing. The stock had a trading volume of 1,262,648 shares, compared to its average volume of 1,098,555. (NASDAQ:CLVS). Natixis accumulated 3,426 shares. Energy Recovery, Inc. (ERII) has declined 27.39% since January 12, 2017 and is downtrending. It has underperformed by 8.11% the S&P500. The other 14, though not evenly; between analysts who think you should buy Baker Hughes, a GE company versus those who think you should sell it.

For the ongoing Fiscal Quarter, 6 analysts have an average earnings forecast of $-1.27 per share.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. The stock increased 0.93% or $0.575 during the last trading session, reaching $62.585. About 2.33M shares traded or 37.10% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since January 9, 2017 and is uptrending. It has outperformed by 109.15% the S&P500.

Investors sentiment increased to 0.79 in Q3 2017. Its up 0.51, from 1.04 in 2017Q2. 78 funds opened positions while 211 raised stakes. Moreover, Tocqueville Asset Management Limited Partnership has 0.07% invested in The Brink's Company (NYSE:BCO) for 75,128 shares. Hanseatic Mngmt Services invested in 0.27% or 2,893 shares. 368,255 were reported by Mariner Wealth Limited Liability. Wells Fargo & Company Mn reported 273,094 shares stake. First Quadrant LP Ca reported 26,200 shares. Godshalk Welsh Mgmt holds 54,700 shares. (NYSE:AIG) for 32,146 shares. Eaton Vance Mgmt has 0.03% invested in American International Group, Inc. Rhumbline Advisers now owns 47,501 shares of the biopharmaceutical company's stock worth $4,448,000 after buying an additional 2,370 shares in the last quarter.

CSX (NASDAQ:CSX) PT Set at $55.00 by Scotiabank
It turned negative, as 56 investors sold CSX shares while 351 reduced holdings. 65 funds opened positions while 204 raised stakes. After $0.35 actual EPS reported by Ladder Capital Corp for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Thermo Fisher Scientific Inc. (TMO) Holdings Cut by Bremer Trust National Association
Pennsylvania-based Bryn Mawr Tru has invested 1.31% in Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on January, 30. Goldman Sachs upgraded the shares of TMO in report on Tuesday, December 8 to "Americas Conviction Buy List" rating.

Corbyn will come round to supporting second referendum, says Lord Adonis
Blair feels that the United Kingdom people should be able to vote again on Brexit after the final deal is agreed with the EU. Mr Blair accused his party on Thursday of making a tactical error by failing to oppose and reverse the impact of Brexit .

In other news, Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction on Friday, December 8th. Dimensional Fund Advisors Lp, Texas-based fund reported 40,391 shares. Farmers Bankshares stated it has 9,037 shares. 12,152 are owned by Tower Rech Cap Ltd Liability Co (Trc).

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. General Electric Company had 81 analyst reports since July 21, 2015 according to SRatingsIntel. On Monday, May 29 the stock rating was downgraded by Raymond James to "Market Perform". Morgan Stanley maintained it with "Overweight" rating and $86 target in Thursday, November 2 report. The stock of American International Group, Inc. The firm has "Buy" rating by Stifel Nicolaus given on Friday, February 26. Suntrust Robinson maintained the stock with "Buy" rating in Wednesday, August 24 report. (NYSE:AIG) rating on Monday, November 13. Sidoti has "Neutral" rating and $94 target. (NASDAQ:CLVS) earned "Neutral" rating by Piper Jaffray on Monday, April 4. Keefe Bruyette & Woods has "Buy" rating and $74.0 target. (NYSE:AIG) on Monday, December 12 to "Outperform" rating. The rating was maintained by Deutsche Bank on Friday, March 11 with "Hold".

Analysts await Express, Inc. (NASDAQ:CLVS) to report earnings on February, 28.

Analysts are also projecting an Average Revenue Estimate for Clovis Oncology, $20920 in the Current Quarter. PWR's profit will be $60.53 million for 24.45 P/E if the $0.39 EPS becomes a reality. Waters Parkerson & Lc holds 1.94% or 907,771 shares in its portfolio. The short ratio for CLVS is 6.11 while that of UNT is just 8.93.

Investors sentiment decreased to 1.44 in Q3 2017. It dived, as 48 investors sold CLVS shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. Citigroup accumulated 285,573 shares. Macquarie Grp Inc Ltd has invested 0.08% in Clovis Oncology, Inc. Invesco Limited reported 480,582 shares or 0.01% of all its holdings. The shares now trade at $25.50 and have been able to report a change of 7.50% over the past one week. Franklin Resource Inc owns 2.32M shares. Royal Financial Bank Of Canada holds 82,512 shares. Analysts are turning out to be more optimistic than before, with 9 of analysts who cover Clovis Oncology, Inc. (NASDAQ:CLVS). Gabelli Funds Ltd holds 15,400 shares. Therefore 38% are positive. Greenwood Capital Associates LLC grew its holdings in shares of Clovis Oncology by 4.0% during the second quarter. The stock presently has a consensus rating of "Buy" and a consensus price target of $91.83. American Century Companies holds 0.01% of its portfolio in Clovis Oncology, Inc. The stock has "Outperform" rating by Robert W. Baird on Wednesday, September 2. The firm earned "Buy" rating on Wednesday, September 21 by Stifel Nicolaus. (NASDAQ:CLVS) has "Buy" rating given on Monday, July 31 by Leerink Swann. Fred Alger Mgmt has invested 0.32% in Clovis Oncology, Inc. RBC Capital Markets has "Hold" rating and $80.0 target. The institutional investor held 36,853 shares of the oil refining and marketing company at the end of 2017Q3, valued at $3.11M, up from 33,109 at the end of the previous reported quarter.

Other reports by

Discuss This Article